Celebrating the close of our historic, five-year $350 million grants to nine nonprofit partners.
Since our founding, we’ve led with purpose to make a lasting impact for patients, communities and society.
2023 marked the close of our historic five-year, $350 million commitment to create long-term impact through donations to nine non-profit organizations providing equitable access to health care, addressing systemic barriers in education and building community resiliency. This commitment has touched hundreds of thousands of lives and exemplifies the responsibility and privilege of everyone at AbbVie to support our communities, better our society and serve patients.
Watch below to learn more about how these investments are helping our partners make a long-lasting impact.
In 2020, we launched a $50 million, five-year commitment to six nonprofit partners advancing health and education equity in Black and other marginalized communities. Through the employee matching program, we’ve raised an additional $2.5 million to advance racial equity. Learn how our partners are progressing on this important work.
Our partners:
We aid communities in times of disasters by donating AbbVie medicines, equipping nonprofit partners with needed resources, and delivering relief to our employees.
We’ve partnered with nonprofit organizations to support relief efforts in Ukraine and surrounding countries, and ensure patients continue to have access to our life-saving medicines.
We committed $1 million to disaster response and relief efforts in the wake of the devastating earthquakes in Turkey and Syria.
countries have received our donated medicines since 2013
provided to eligible employees impacted by natural disasters in 2022 through the AbbVie Foundation Employee Relief program
donated to disaster relief organizations in 2022
Our community partners are advancing health equity for marginalized populations and patients worldwide through community-centered programs that drive systemic change.
The product-specific site Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals that are not approved in other countries or region. If you are a resident of a country other than those to which the site is directed, please return to AbbVie.com or contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence. The Internet site that you have requested may not be optimized to your screen size. Do you wish to continue to this product-specific site?